Stockscreener 앱 받기
20.33
0.20%
-0.0313
전일 마감가:
$20.36
열려 있는:
$20.19
하루 거래량:
3.01M
Relative Volume:
0.34
시가총액:
$10.46B
수익:
$10.89B
순이익/손실:
$-241.00M
주가수익비율:
-76.54
EPS:
-0.2656
순현금흐름:
$340.00M
1주 성능:
-5.84%
1개월 성능:
+3.83%
6개월 성능:
-17.16%
1년 성능:
-42.11%
1일 변동 폭
$19.91
$20.48
1주일 범위
$19.91
$21.48
52주 변동 폭
$17.40
$37.74
박스터 인터내셔널 Stock (BAX) Company Profile
명칭
Baxter International Inc
전화
(224) 948-2000
주소
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
20.32 | 10.48B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
500.90 | 180.01B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
177.84 | 50.25B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
86.90 | 42.27B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
48.27 | 39.67B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.92 | 37.45B | 5.40B | 1.49B | 1.78B | 10.12 |
박스터 인터내셔널 Stock (BAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 다운그레이드 | Argus | Buy → Hold |
| 2025-08-04 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-08-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-26 | 재개 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | Argus | Hold → Buy |
| 2025-02-20 | 재개 | Barclays | Overweight |
| 2024-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-12-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-06-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-18 | 재확인 | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-18 | 재확인 | Raymond James | Outperform |
| 2022-02-18 | 재확인 | Stifel | Buy |
| 2022-02-18 | 재확인 | UBS | Neutral |
| 2022-02-18 | 재확인 | Wells Fargo | Overweight |
| 2022-02-11 | 개시 | Goldman | Neutral |
| 2022-01-07 | 재개 | Citigroup | Buy |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-09-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-12-15 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-09-04 | 다운그레이드 | Argus | Buy → Hold |
| 2020-06-24 | 개시 | Oppenheimer | Outperform |
| 2020-03-19 | 업그레이드 | Stifel | Hold → Buy |
| 2020-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-13 | 개시 | Goldman | Buy |
| 2020-01-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-01-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-01-02 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | 업그레이드 | Argus | Hold → Buy |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-05-17 | 재개 | Piper Jaffray | Overweight |
| 2018-02-06 | 재확인 | Citigroup | Neutral |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
모두보기
박스터 인터내셔널 주식(BAX)의 최신 뉴스
Understanding Baxter International's Role in MedTech - www.whatjobs.com
Baxter at Citi’s MedTech Day: Strategic Shifts Amidst Challenges - Investing.com
Baxter International Inc To Go Ex-Dividend On February 27th, 2026 With 0.01 USD Dividend Per Share - 富途牛牛
Siemens, Baxter, Hilton & more dividends 2026 • Vienna Stock Exchange - Wiener Börse
Ex-Dividend Reminder: MGE Energy, Labcorp Holdings and Baxter International - Nasdaq
Infusion Stand Market Is Going to Boom | BD • Baxter International • Smiths Medical - openPR.com
Baxter Investors Face a Test of Patience Amid Corporate Overhaul - AD HOC NEWS
Is Baxter International (BAX) Pricing In Its Turnaround After Years Of Share Price Weakness? - simplywall.st
Baxter International's $3 Billion Sales Base Facing Earnings Pressure - Smartkarma
Baxter is one of the S&P 500’s worst performers today. Earnings were brutal. - MSN
Baxter’s Ongoing Losses And Impairments Test The Investment Narrative - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Through Challenges with Strategic Resilience - DirectorsTalk Interviews
Is Baxter International Inc (BAX) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Baxter Hopes Recovery Under New CEO, Faces Near-Term Pressure - Citeline News & Insights
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading - Yahoo Finance
Patient Lifting Equipment Market is Going to Boom | Baxter International Inc., ICU Medical, Inc., B. Braun Melsungen AG - openPR.com
The Top 5 Analyst Questions From Baxter's Q4 Earnings Call - Finviz
Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider - GlobeNewswire Inc.
Benefits of Device Connectivity - Baxter
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Anti-Venom Market 2026-2035 Top Key Playres: Baxter - openPR.com
Demystifying Baxter International: Insights From 4 Analyst Reviews - Benzinga
Baxter International Inc (BAX) Shares Up 3.99% on Feb 17 - GuruFocus
BAX: Goldman Sachs Lowers Price Target on Baxter International | - GuruFocus
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case - Sahm
Baxter International (BAX) Returns To Quarterly Loss And Tests Earnings Recovery Narrative - Sahm
Aug Sectors: Is Baxter International Inc a potential multi baggerJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
UBS Maintains Neutral on BAX Baxter International Inc. Feb 2026 - Meyka
Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment - Yahoo Finance
Baxter’s New Decentralized Model Tests Earnings And Valuation Expectations - Yahoo Finance
Quarterly Trades: Does Baxter International Inc outperform in volatile marketsTrend Reversal & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Baxter International Stock Was Tumbling Today - AOL.com
Is Baxter International Inc. stock a top momentum playJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - mfd.ru
Is Baxter International Inc. stock a momentum leaderJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Baxter Overhaul Shifts To Decentralized Model As Recovery Timelines Extend - simplywall.st
Is Baxter International Inc. stock risky to hold nowProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Product Playbook - AD HOC NEWS
Baxter International (NYSE:BAX) Price Target Lowered to $17.00 at The Goldman Sachs Group - MarketBeat
A Quick Look at Today's Ratings for Baxter International Inc(BAX.US), With a Forecast Between $20 to $25 - 富途牛牛
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
The Truth About Baxter International Inc.: Hidden Healthcare Giant or Total Snooze Stock? - AD HOC NEWS
Baxter lays off 90 employees from hurricane-hit unit - Medical Buyer
Baxter International Earnings Call: Growth Meets Margin Squeeze - The Globe and Mail
BAX Q4 Deep Dive: Mixed Segment Performance and Margin Pressures Shape Outlook - Finviz
Looking Into Baxter International Inc's Recent Short Interest - Benzinga
Barclays Lowers Price Target for Baxter Intl (BAX) While Maintai - GuruFocus
Jefferies Financial Group Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Barclays Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter sales up 8% to USD 2.97B in Q4 2025 - Medical Buyer
박스터 인터내셔널 (BAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.39%
0.11%
자본화:
|
볼륨(24시간):